Sharemaestro company-news research for Entera Bio Ltd (ENTX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest ENTX news and sentiment

Entera Bio Ltd

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score50Neutral is 50
Early balanced news score 15/100 evidence confidence 100% direct company focus 4 current stories across 2 publishers
Latest weekly closeUSD 2.74week of 25 Sep 2026
Main news subjectMarket update72/100 share of current news
News data statusPartial2 duplicate stories removed

Current company news

Early balanced news score

4 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone43/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Entera Bio Ltd (ENTX) Stock Price, Quote, News & History Benzinga · 11 Sep 2026 12:22

What supports the score

Direct evidence

4 current stories are mapped specifically to ENTX.

What limits the score

Source breadth

Only 2 publishers currently contribute to the measured read.

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.002.

Confidence

Confidence is 15/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
15/100
Confidencethin evidence
100%/100
Company news4 company stories
100/100
Story agreement0/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
11 Sep: 1 stories 11 Sep: tone 50, 1 stories 95505
29 Aug13 Sep27 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence0
0.002 after freshness weighting
Source breadth40
2 independent publishers
Company relevance100
share tied directly to this company
Freshness2
recency-weighted evidence
Agreement100
how closely stories agree
Publisher mix0
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks17 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr 2026: close 1.26, indexed 100.010 Apr 2026: close 1.15, indexed 91.317 Apr 2026: close 1.28, indexed 101.624 Apr 2026: close 1.12, indexed 88.901 May 2026: close 1.1, indexed 87.308 May 2026: close 1.3, indexed 103.215 May 2026: close 1.26, indexed 100.022 May 2026: close 1.24, indexed 98.429 May 2026: close 1.35, indexed 107.105 Jun 2026: close 1.18, indexed 93.712 Jun 2026: close 1.23, indexed 97.619 Jun 2026: close 1.21, indexed 96.026 Jun 2026: close 1.63, indexed 129.403 Jul 2026: close 1.66, indexed 131.710 Jul 2026: close 1.655, indexed 131.317 Jul 2026: close 1.98, indexed 157.124 Jul 2026: close 2.05, indexed 162.731 Jul 2026: close 2.99, indexed 237.307 Aug 2026: close 2.87, indexed 227.814 Aug 2026: close 2.89, indexed 229.421 Aug 2026: close 3.23, indexed 256.328 Aug 2026: close 3.03, indexed 240.504 Sep 2026: close 3.0, indexed 238.111 Sep 2026: close 2.84, indexed 225.418 Sep 2026: close 2.96, indexed 234.925 Sep 2026: close 2.745, indexed 217.9 05 Jun 2026: news score 50, close 1.18, 1 stories5012 Jun 2026: news score 50, close 1.23, 1 stories19 Jun 2026: news score 49, close 1.21, 2 stories26 Jun 2026: news score 50, close 1.63, 7 stories5003 Jul 2026: news score 50, close 1.66, 7 stories10 Jul 2026: news score 50, close 1.655, 8 stories17 Jul 2026: news score 50, close 1.98, 12 stories5024 Jul 2026: news score 55, close 2.05, 14 stories31 Jul 2026: news score 55, close 2.99, 31 stories07 Aug 2026: news score 54, close 2.87, 43 stories5414 Aug 2026: news score 46, close 2.89, 51 stories21 Aug 2026: news score 43, close 3.23, 50 stories28 Aug 2026: news score 47, close 3.03, 39 stories4704 Sep 2026: news score 49, close 3.0, 25 stories11 Sep 2026: news score 50, close 2.84, 17 stories18 Sep 2026: news score 50, close 2.96, 8 stories5025 Sep 2026: news score 50, close 2.745, 3 stories50 Price index 276.6 171.8 67.0 News score 100 50 0
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
26-week price+117.9%latest close 2.74
News score change+0first to latest comparable week
One-week response+4.2%Price confirming higher
Fair-value position+67.8%Materially above fair value
WeekNews scoreCloseWeekly move
25 Sep 202650USD 2.745-7.3%
18 Sep 202650USD 2.96+4.2%
11 Sep 202650USD 2.84-5.3%
04 Sep 202649USD 3.0-1.0%
28 Aug 202647USD 3.03-6.2%
21 Aug 202643USD 3.23+11.8%
14 Aug 202646USD 2.89+0.7%
07 Aug 202654USD 2.87-4.0%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update503 stories · 75%
Earnings431 stories · 25%

Source mix

Where the evidence comes from

0/100 independence
careplusvn.com431 stories · 25%
GlobeNewswire431 stories · 25%
Benzinga501 stories · 25%
MarketBeat501 stories · 25%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences1Financial Markets1

Earlier readings

How the score has changed

41 comparable readings · 118 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move-151 to 50 · Broadly stable
Observed range43–6050 is the neutral baseline
Evidence depth2stories at latest stored reading · +1
Confidence14/100Provisional · -14
31 May50 neutral27 Sep 06:16
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
27 Sep 06:1650+014/100 (-4)2 (-15)Provisional
11 Sep 23:5950+318/100 (-14)17 (-22)Provisional
28 Aug 23:5947+132/100 (0)39 (-2)Provisional
27 Aug 23:5946+032/100 (0)41 (0)Provisional
26 Aug 23:5946+032/100 (-4)41 (-10)Provisional
24 Aug 23:5946-236/100 (+1)51 (0)Measured
23 Aug 23:5948+535/100 (+1)51 (-1)Provisional
20 Aug 23:5943-134/100 (+1)52 (0)Provisional

Source headlines

The news behind the score

Showing 1-4 of 4

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
BenzingaDirect company coverageScored from headline

Entera Bio Ltd (ENTX) Stock Price, Quote, News & History

Published
11 Sep 2026 12:22
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 13.7d old
Duplicates
1 consolidated
#343Tone
GlobeNewswireDirect company coverageScored from headline

Correction: Entera to Participate in Upcoming Fall Investor Conferences

Published
27 Aug 2026 13:44
News subject
Market update
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 28/100
30-day weight
0.2% of the score · 28.6d old
Duplicates
1 consolidated
#4—Not directional
MarketBeatDirect company coverageStored article

Entera Bio (ENTX) Short Interest & Short Float | Updated Aug 2026

Entera Bio (ENTX) had a short interest of 956,758 shares as of August 14, 2026, representing 0.62% of its public float, which is a 16.81% decrease from the prior report. The short interest ratio is 1.9 days to cover, indicating that it would take less than two days for short sellers to cover their positions at average trading volume. The article provides a historical overview of ENTX's short interest data, detailed metrics, and frequently asked questions about short selling.

Financial MarketsLife Sciences
Published
26 Aug 2026 18:32
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 29.4d old
Duplicates
1 consolidated

Earlier company news

ENTX news archive

Showing 61-78 of 78 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Jul 22 2026
Simply Wall StreetArchivedNeutral tone

Entera Bio Leads Our Top 3 Penny Stocks To Consider

This article identifies three penny stocks—Entera Bio (ENTX), Vuzix (VUZI), and MacroGenics (MGNX)—that show potential for growth despite their current financial challenges. Entera Bio, a clinical-stage biotech company, is advancing towards Phase 3 trials for its osteoporosis treatment. Vuzix, an AI-powered smart glasses manufacturer, faces financial hurdles but continues to innovate, while MacroGenics, a biopharmaceutical company, is reducing losses and recently secured a significant milestone payment.

EarningsFinanceFinancial MarketsLife SciencesTechnology
Published
22 Jul 2026 12:11
Catalyst
Earnings
Coverage
Direct company
Duplicates
3 consolidated
Jul 21 2026
Market sourceArchivedPositive tone

Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know

Entera Bio (ENTX) shares have surged 34.5% in the past month due to positive FDA feedback on the Phase III study design for its lead candidate, EB613, an oral treatment for postmenopausal osteoporosis. The FDA supports a single 12-month Phase III study, which could lead to the first oral anabolic osteoporosis treatment. The company plans to start the pivotal study in late 2026, with results expected in late 2028, and is leveraging the 505(b)(2) pathway with Eli Lilly's Forteo.

BiotechClinical TrialsEarningsEarnings Per ShareFda ApprovalFinancial Markets
Published
21 Jul 2026 15:09
Catalyst
Earnings
Coverage
Direct company
Duplicates
2 consolidated
Jul 17 2026
www.timothysykes.comArchivedNeutral tone

Entera Bio Ltd. (ENTX) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Entera Bio Ltd. (ENTX) stock on NASDAQ. It includes current stock price, recent performance data, and indicates that there are no analyst ratings or earnings information currently available for the company. The page also features an advertisement for Timothy Sykes, a penny stock trader.

EarningsFinancial MarketsLife Sciences
Published
17 Jul 2026 12:10
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
Stock TitanArchivedNeutral tone

Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs

Entera Bio's CEO, Toledano Miranda Jayne, received two grants of stock-settled Restricted Stock Units (RSUs) on July 14, 2026, in lieu of cash compensation. One grant, totaling 72,993 ordinary shares, replaced her 2025 annual cash bonus, while the other, for 347,567 shares, substituted $100,000 of her 2026 base salary. These RSUs will vest quarterly over one year, with full acceleration upon a Change in Control, as approved by the board and shareholders.

EarningsLife Sciences
Published
16 Jul 2026 21:10
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
Stock TitanArchivedPositive tone

Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool

Entera Bio (NASDAQ: ENTX) shareholders approved an increase in the authorized ordinary shares from 140,010,000 to 350,000,000 and added 2,500,000 ordinary shares to the 2018 Equity Incentive Plan. These approvals were made during the company's 2026 Annual Meeting, alongside the re-election of Class III directors and compensation-related proposals. The changes are expected to provide the company with greater flexibility for future equity awards and capital raising.

EarningsFinanceLife Sciences
Published
16 Jul 2026 21:10
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
BitgetArchivedNeutral tone

Entera Bio shareholders approve authorized share increase at annual meeting

Entera Bio shareholders approved an increase in authorized ordinary shares from 140,010,000 to 350,000,000 at their 2026 annual meeting on July 14, 2026. They also adopted a one-time increase of 2,500,000 ordinary shares for the 2018 Equity Incentive Plan and ratified Kesselman & Kesselman as the independent auditor. An advisory vote on named executive officer pay also passed.

Finance
Published
16 Jul 2026 21:09
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated

Provider matches checked

Provider mentions not used in the score

4 not scored

A news provider linked these stories to ENTX, but the headline and available text are not mainly about Entera Bio Ltd. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of ENTX sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context